Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vipivotide Tetraxetan SCHEMBL18040251 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21881849 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21872782 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729006 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21316439 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24612683 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL22313039 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729005 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21501570 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL29648484 | 1.00 | FOLH1 (1.00) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239829-A2 | SYSTEMS AND METHODS FOR ASSESSING DISEASE BURDEN AND PROGRESSION | PROGENICS PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
| US-11657508-B2 | Systems and methods for platform agnostic whole body image segmentation | EXINI DIAGNOSTICS AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-20230098279-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ENDOCYTE, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220220085-A1 | METHODS FOR PREPARING PSMA CONJUGATES | ENDOCYTE, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220125957-A1 | METHODS OF TREATING CANCER | SATHEKGE MIKE (ZA) | 2022-04-28 | — | — | US | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210161911-A1 | METHODS OF TREATING CANCER | ENDOCYTE INC (US) | 2021-06-03 | — | — | US | disclosed |
| US-10665346-B2 | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications | PROGENICS PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200126666-A1 | NETWORK FOR MEDICAL IMAGE ANALYSIS, DECISION SUPPORT SYSTEM, AND RELATED GRAPHICAL USER INTERFACE (GUI) APPLICATIONS | CITIZENS BANK, N.A. | 2020-04-23 | — | — | US | disclosed |
| WO-2020061293-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061458-A1 | METHODS OF TREATING CANCER | ENDOCYTE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2019204335-A1 | METHODS OF TREATING CANCER | ENDOCYTE, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2019-09-03 | — | — | US | disclosed |
| US-10377778-B2 | Lead and thorium compounds | Sciencons AS (NO) | 2019-08-13 | — | — | US | disclosed |
| US-10340046-B2 | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications | PROGENICS PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190177345-A1 | NOVEL LEAD AND THORIUM COMPOUNDS | Sciencons AS (NO) | 2019-06-13 | — | — | US | disclosed |
| US-20180144828-A1 | NETWORK FOR MEDICAL IMAGE ANALYSIS, DECISION SUPPORT SYSTEM, AND RELATED GRAPHICAL USER INTERFACE (GUI) APPLICATIONS | CITIZENS BANK, N.A. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377778-B2 | Lead and thorium compounds | PSMA7, PSMA2, PSMA1 | FOLH1 6/4885 |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | FOLH1 2/4885 |
| US-11657508-B2 | Systems and methods for platform agnostic whole body image segmentation | HTR3D, SSTR3, ERBB3 | FOLH1 709/4885 |
| US-20230098279-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | FOLH1 42/4885 |
| US-20220125957-A1 | METHODS OF TREATING CANCER | PAICS, FOLH1, INHA | FOLH1 2/4885 |
| US-20220220085-A1 | METHODS FOR PREPARING PSMA CONJUGATES | FOLH1, PSMA6, PSMA1 | FOLH1 1/4885 |
| US-20210161911-A1 | METHODS OF TREATING CANCER | FOLH1, PSMA1, PSMA2 | FOLH1 1/4885 |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | KLK3, SHBG, SELPLG | FOLH1 8/4885 |
| US-20190177345-A1 | NOVEL LEAD AND THORIUM COMPOUNDS | PSMA7, PSMA2, PSMA1 | FOLH1 6/4885 |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | PSMA6, PSMA2, PSMA1 | FOLH1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.